CytomX 
Welcome,         Profile    Billing    Logout  
 6 Products   0 Diseases  6 Products   5 Trials   255 News 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sovipostobart (BMS-986249) / BMS
NCT03369223 / 2018-000416-21: A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Hourglass May 2021 - Dec 2021 : From trial in combination with Opdivo for melanoma
Checkmark Safety data from trial in combination with Yervoy and Opdivo for solid tumors at ASCO 2020
May 2020 - May 2020: Safety data from trial in combination with Yervoy and Opdivo for solid tumors at ASCO 2020
Completed
1/2
607
Europe, Canada, US, RoW
BMS-986249, Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016
Bristol-Myers Squibb
Advanced Cancer
11/24
11/24
pacmilimab (CX-072) / CytomX
2019-000999-42: A study of CX-072 in Combination with other Anticancer Therapy in Adults with Solid Tumors

Not yet recruiting
2
170
Europe
CX-072, Yervoy, CX-072, Concentrate for solution for infusion, Yervoy
CytomX Therapeutics, Inc, CytomX Therapeutics, Inc.
Treatment of solid tumors, including advanced/unresectable or metastatic cancer and neoadjuvant/resectable, Treatment of cancer, Diseases [C] - Cancer [C04]
 
 
CTMX-2009-002, NCT04596150 / 2020-004618-36: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Completed
2
125
Europe, US, RoW
CX-2009, CX-072
CytomX Therapeutics, CytomX Therapeutics, Inc.
Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative
06/23
06/23
2020-004618-36: Study to test CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072 in Advanced Triple-Negative Breast Cancer Estudio para evaluar CX-2009 en el cáncer de mama avanzado positivo para receptores hormonales/negativo para el receptor HER2, y de CX-2009 como monoterapia y en combinación con CX-072 en el cáncer de mama avanzado triple negativo (CTMX-2009-002)

Not yet recruiting
2
150
Europe
CX-2009, CX-072, CX-2009, CX-072, Powder for infusion, Solution for infusion
CytomX Therapeutics, Inc., CytomX Therapeutics, Inc.
HR-positive/HER2-negative breast cancerTriple-negative breast cancer Cáncer de mama positivo para receptores hormonales/negativo para elreceptor HER2Cáncer de mama avanzado triple negativo, Breast Cancer Cáncer de mama, Diseases [C] - Cancer [C04]
 
 
CX-2029 / CytomX
PROCLAIM-CX-2029, NCT03543813 / 2018-001456-34: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

Completed
1/2
133
Europe, US, RoW
CX-2029
CytomX Therapeutics
Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma, Esophageal Cancer
06/23
06/23
CX-904 / CytomX, Amgen
CTMX-904-101, NCT05387265: A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

Active, not recruiting
1
83
US
CX-904
CytomX Therapeutics
Solid Tumors
08/25
08/25
BMS-986288 / BMS
2021-004284-27: An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Studio sperimentale immuno-terapico di BMS-986288 somministrato in monoterapia e in combinazione con nivolumab in tumori solidi avanzati

Not yet recruiting
1/2
200
Europe
NIVOLUMAB - 10ml vial- COMMERCIAL, anti-CTLA-4 NF Probody mAb, [BMS-936558], [BMS-986288], Concentrate for solution for injection/infusion, Solution for infusion, Opdivo (100 mg/10 ml)
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION, Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation
Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC). Tumori solidi in stadio avanzato (carcinoma a cellule squamose della testa e del collo (SCCHN), carcinoma polmonare non a piccole cellule (NSCLC), melanoma cutaneo, carcinoma mammario triplo negativo (TNBC), carcinoma a cellule renali (RCC), carcinoma uroteliale, tumore gastrico, esofageo, della cervice uterina e del colon-retto (CRC)., Advanced solid tumors Tumori solidi in stadio avanzato, Diseases [C] - Cancer [C04]
 
 
NCT03994601 / 2021-004284-27: An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

Completed
1/2
219
Europe, Canada, US, RoW
BMS-986288, Nivolumab, Opdivo, BMS-936558, Regorafenib
Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation
Advanced Cancer
08/24
08/24
CX-801 / CytomX
KEYNOTE-F95, NCT06462794: First In Human Study of CX-801 in Advanced Solid Tumors

Recruiting
1
121
US
CX-801, pembrolizumab, KEYTRUDA®
CytomX Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult
02/28
06/29
CX-2051 / CytomX
CTMX-2051-101, NCT06265688: First In Human Study of CX-2051 in Advanced Solid Tumors

Recruiting
1
124
US
CX-2051
CytomX Therapeutics
Solid Tumor, Adult
11/27
03/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sovipostobart (BMS-986249) / BMS
NCT03369223 / 2018-000416-21: A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Hourglass May 2021 - Dec 2021 : From trial in combination with Opdivo for melanoma
Checkmark Safety data from trial in combination with Yervoy and Opdivo for solid tumors at ASCO 2020
May 2020 - May 2020: Safety data from trial in combination with Yervoy and Opdivo for solid tumors at ASCO 2020
Completed
1/2
607
Europe, Canada, US, RoW
BMS-986249, Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016
Bristol-Myers Squibb
Advanced Cancer
11/24
11/24
pacmilimab (CX-072) / CytomX
2019-000999-42: A study of CX-072 in Combination with other Anticancer Therapy in Adults with Solid Tumors

Not yet recruiting
2
170
Europe
CX-072, Yervoy, CX-072, Concentrate for solution for infusion, Yervoy
CytomX Therapeutics, Inc, CytomX Therapeutics, Inc.
Treatment of solid tumors, including advanced/unresectable or metastatic cancer and neoadjuvant/resectable, Treatment of cancer, Diseases [C] - Cancer [C04]
 
 
CTMX-2009-002, NCT04596150 / 2020-004618-36: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Completed
2
125
Europe, US, RoW
CX-2009, CX-072
CytomX Therapeutics, CytomX Therapeutics, Inc.
Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative
06/23
06/23
2020-004618-36: Study to test CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072 in Advanced Triple-Negative Breast Cancer Estudio para evaluar CX-2009 en el cáncer de mama avanzado positivo para receptores hormonales/negativo para el receptor HER2, y de CX-2009 como monoterapia y en combinación con CX-072 en el cáncer de mama avanzado triple negativo (CTMX-2009-002)

Not yet recruiting
2
150
Europe
CX-2009, CX-072, CX-2009, CX-072, Powder for infusion, Solution for infusion
CytomX Therapeutics, Inc., CytomX Therapeutics, Inc.
HR-positive/HER2-negative breast cancerTriple-negative breast cancer Cáncer de mama positivo para receptores hormonales/negativo para elreceptor HER2Cáncer de mama avanzado triple negativo, Breast Cancer Cáncer de mama, Diseases [C] - Cancer [C04]
 
 
CX-2029 / CytomX
PROCLAIM-CX-2029, NCT03543813 / 2018-001456-34: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

Completed
1/2
133
Europe, US, RoW
CX-2029
CytomX Therapeutics
Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma, Esophageal Cancer
06/23
06/23
CX-904 / CytomX, Amgen
CTMX-904-101, NCT05387265: A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

Active, not recruiting
1
83
US
CX-904
CytomX Therapeutics
Solid Tumors
08/25
08/25
BMS-986288 / BMS
2021-004284-27: An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Studio sperimentale immuno-terapico di BMS-986288 somministrato in monoterapia e in combinazione con nivolumab in tumori solidi avanzati

Not yet recruiting
1/2
200
Europe
NIVOLUMAB - 10ml vial- COMMERCIAL, anti-CTLA-4 NF Probody mAb, [BMS-936558], [BMS-986288], Concentrate for solution for injection/infusion, Solution for infusion, Opdivo (100 mg/10 ml)
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION, Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation
Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC). Tumori solidi in stadio avanzato (carcinoma a cellule squamose della testa e del collo (SCCHN), carcinoma polmonare non a piccole cellule (NSCLC), melanoma cutaneo, carcinoma mammario triplo negativo (TNBC), carcinoma a cellule renali (RCC), carcinoma uroteliale, tumore gastrico, esofageo, della cervice uterina e del colon-retto (CRC)., Advanced solid tumors Tumori solidi in stadio avanzato, Diseases [C] - Cancer [C04]
 
 
NCT03994601 / 2021-004284-27: An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

Completed
1/2
219
Europe, Canada, US, RoW
BMS-986288, Nivolumab, Opdivo, BMS-936558, Regorafenib
Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation
Advanced Cancer
08/24
08/24
CX-801 / CytomX
KEYNOTE-F95, NCT06462794: First In Human Study of CX-801 in Advanced Solid Tumors

Recruiting
1
121
US
CX-801, pembrolizumab, KEYTRUDA®
CytomX Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult
02/28
06/29
CX-2051 / CytomX
CTMX-2051-101, NCT06265688: First In Human Study of CX-2051 in Advanced Solid Tumors

Recruiting
1
124
US
CX-2051
CytomX Therapeutics
Solid Tumor, Adult
11/27
03/29

Download Options